REGULATORY

MHLW Device Review Chief Pledges Evidence-Based Approvals amid Diversifying Technologies

By Sakura Kono August 6, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

With new technologies―from software-based devices to regenerative medicine products―reshaping the healthcare landscape, the Ministry of Health, Labor and Welfare (MHLW) aims to maintain rigorous, evidence-based reviews while adapting to an increasingly diverse array of modalities. Yumiko Nomura, new director of…

To read the full story

MHLW Shuffles Senior Bureaucrats, Miyamoto to Head Pharma Safety Bureau
July 2, 2025

REGULATORY

Finance Minister Backs Further Debate on Low-Risk Medicines: CEFP Minutes
May 29, 2026
LDP HQ Finalizes Recommendations ahead of Growth Strategy
May 29, 2026
Japan Eyes Broader Healthcare Measures Addressing Sex-Based Health Issues
May 28, 2026
MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…